Biographical information for each continuing director, including each such individuals principal
occupation, business experience, and education, and an explanation of the qualifications, skills, and experience that we believe are relevant to such individuals service on our Board, are set forth below. Unless otherwise indicated, principal
occupations shown for each continuing director have extended for five or more years.
Hans E. Bishop has served as a member of our Board
since October 2018. Mr. Bishop has more than 30 years of experience in the biotechnology industry. Mr. Bishop is a founder of and has served as President of Altos Labs, Inc. (Altos Labs), a private biotechnology company, since January
2022. Prior to Altos Labs, Mr. Bishop served as the Chief Executive Officer of GRAIL, Inc., a healthcare company, from June 2019 until October 2021, following its acquisition by Illumina, Inc. (Illumina). Mr. Bishop founded Juno in July
2013 and served as Junos President and Chief Executive Officer until its acquisition by Celgene in March 2018. Prior to Juno, Mr. Bishop served as Executive in Residence at Warburg Pincus, a multinational private equity firm. Earlier in
his career, Mr. Bishop served as Executive Vice President and Chief Operating Officer for Dendreon Corporation (Dendreon), which was a public biopharmaceutical company developing cancer immunotherapies during his tenure. Prior to Dendreon,
Mr. Bishop served as President of Specialty Medicine at Bayer Healthcare, a multinational pharmaceutical and life sciences company, and before that served as Senior Vice President of Global Commercial Operations at Chiron Corporation, which was
a multinational biotechnology company, where he was also Vice President and General Manager of European Biopharmaceuticals. He currently serves on the boards of directors of Agilent Technologies, Inc., a public instrumentation manufacturing company,
and Lyell Immunopharma, Inc. (Lyell Immunopharma), a public cellular therapy company. Mr. Bishop previously served on the board of directors of Celgene and JW Therapeutics. Mr. Bishop received his B.A. in Chemistry from Brunel University
in London. We believe Mr. Bishop is qualified to serve on our Board because of his extensive management experience within the pharmaceutical and biotechnology industries and his academic experience.
Robert Nelsen has served as a member of our Board since October 2018. Mr. Nelsen is a co-founder
and has served as Managing Director of ARCH Venture Partners, a venture capital firm focused on early-stage technology companies, since 1994, and has played a significant role in the early sourcing, financing, and development of more than 30
biopharmaceutical companies. Mr. Nelsen currently serves on the boards of directors of several public biotechnology and biopharmaceutical companies, including Brii Biosciences Limited, Denali, Hua Medicine, Lyell Immunopharma, and Vir
Biotechnology, Inc. Mr. Nelsen previously served on the boards of directors of several public biotechnology and biopharmaceutical companies, including Adolor Corporation, Agios Pharmaceuticals, Inc., Beam Therapeutics Inc. (Beam), Bellerophon
Therapeutics, Inc., Fate Therapeutics, Inc., Illumina, Juno, Karuna Therapeutics, Inc., KYTHERA Biopharmaceuticals, Inc., NeurogesX, Inc., Revolution Healthcare Acquisition Corp., Sage Therapeutics, Inc., Sienna Biopharmaceuticals, Inc., Syros
Pharmaceuticals, Inc., and Unity Biotechnology, Inc. He also previously served as Trustee of the Fred Hutchinson Cancer Research Center and as a director of the National Venture Capital Association. Mr. Nelsen received his M.B.A. from the
University of Chicago Booth School of Business and his B.S. in Economics and Biology from the University of Puget Sound. We believe Mr. Nelsen is qualified to serve on our Board because of his venture capital and industry experience, his
extensive experience serving on boards of directors of public biotechnology companies, and his significant academic experience.
Alise S. Reicin, M.D. has served as a member of our Board since December 2020. Dr. Reicin has served as Chief Executive Officer and
President of Tectonic Therapeutic, Inc. (Tectonic), a biotechnology company, since August 2020. Prior to Tectonic, she served as President, Global Clinical Development at Celgene from November 2018 to December 2019. Prior to Celgene, she served as
Head of Global Clinical Development at EMD Serono Inc. (EMD Serono), a pharmaceutical company, from May 2015 to October 2018. Prior to EMD Serono, Dr. Reicin served as Vice President, Program and Pipeline Leadership, Oncology at Merck. Prior to
Merck, she was a faculty member at Columbia Medical School and a physician and researcher at Columbia Presbyterian Hospital. Dr. Reicin serves on the board of directors of Homology Medicines, Inc., a public biopharmaceutical company.
Dr. Reicin received her M.D. from Harvard Medical School and her B.A. in Biochemistry from Barnard College of Columbia University. We believe Dr. Reicin is qualified to serve on our Board because of her extensive clinical expertise and
leadership experience at biopharmaceutical companies.
12